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Abstract
Natural killer (NK) cell-based adoptive immunotherapy is a promising treatment approach for many cancers. However,
development of protocols that provide large numbers of functional NK cells produced under GMP conditions are required
to facilitate clinical studies. In this study, we translated our cytokine-based culture protocol for ex vivo expansion of NK cells
from umbilical cord blood (UCB) hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We
optimized enrichment of CD34
+ cells from cryopreserved UCB units using the CliniMACS system followed by efficient
expansion for 14 days in gas-permeable cell culture bags. Thereafter, expanded CD34
+ UCB cells could be reproducibly
amplified and differentiated into CD56
+CD3
2 NK cell products using bioreactors with a mean expansion of more than 2,000
fold and a purity of .90%. Moreover, expansion in the bioreactor yielded a clinically relevant dose of NK cells (mean:
2610
9 NK cells), which display high expression of activating NK receptors and cytolytic activity against K562. Finally, we
established a versatile closed washing procedure resulting in optimal reduction of medium, serum and cytokines used in the
cell culture process without changes in phenotype and cytotoxic activity. These results demonstrate that large numbers of
UCB stem cell-derived NK cell products for adoptive immunotherapy can be produced in closed, large-scale bioreactors for
the use in clinical trials.
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Introduction
Natural Killer (NK) cells are CD3
2CD56
+ lymphocytes that
exert innate immunity against cancer and viral infections [1].
Recognition and subsequent killing of virus-infected and trans-
formed cells by NK cells is regulated through the balance of signals
from inhibitory and activating receptors [1]. Due to their strong
ability to target tumor cells, NK cells have been described as
promising effectors for adoptive immunotherapy against cancer
[2]. It has been well demonstrated that NK cell alloreactivity can
control relapse of acute myeloid leukemia (AML) without causing
graft-versus-host disease (GVHD) in the setting of haploidentical
stem cell transplantation (SCT) [3]. Moreover, haploidentical NK
cell infusions in adult and childhood AML following lymphocyte
depleting chemotherapy have provided encouraging results [4,5].
However, only a few trials investigating adoptive NK cell infusions
in patients with cancer have been conducted to date. A major
obstacle is that relative small numbers of NK cells can be isolated
from a regular leukapheresis products. This hampers clinical trials
evaluating for NK-cell dose dependent anti-tumor responses in
humans with cancer [6–11]. Therefore, protocols for ex vivo
expansion and activation of NK cells are under investigation
enabling clinical trials at higher NK cell dosages and to permit
multiple NK cell infusions [12–16]. However, most protocols still
deal with technical disadvantages by using supportive feeder cell
lines that could lead to regulatory problems producing NK cell
products for large-scale and multi-center trials. Interestingly, a
recent study by Sutlu et al. reported that large amounts of highly
active NK cells can be produced from peripheral blood in a closed,
automated bioreactor under feeder-free conditions. [17].
Recently, we have described an alternative cytokine-based
culture method with the capability of generating clinically relevant
NK cell products with high cell numbers, high purity and
functionality from umbilical cord blood derived hematopoietic
stem cells (UCB-HSC) [18]. UCB is a very attractive source of
HSC not only for allogeneic SCT, but also for producing a
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An optimal procedure for the clinical-grade generation of UCB
progenitor cell-derived NK cells must include a GMP-compatible
HSC enrichment procedures as well as a closed-system culture
system free of animal products and feeder cells. In the present
study, we have investigated the feasibility of large scale NK cell
generation using cryopreserved UCB units as progenitor cell
source. We have optimized the enrichment of CD34
+ cells from
thawed UCB units using the CliniMACS system. Furthermore, we
have evaluated CD34
+ cells-derived NK cell generation in static
cell culture bags and an automated bioreactor, with the aim of
optimizing fully closed, large-scale production of highly active and
functional NK cells for the use in a phase I dose-finding trial in
elderly AML patients not eligible for allogeneic SCT.
Results
Efficient enrichment of CD34
+ cells from cryopreserved
umbilical cord blood
Theoverallaimofthisstudywastodevelopaclosedexvivoculture
system for the expansion and differentiation of CD34
+ UCB cells
into NK cells followed by the subsequent log-scale generation of
CD56
+CD3
2 NK cells. As the initiation of our culture process
requires hematopoietic progenitor cells, we optimized the CD34
+
enrichment procedure from cryopreserved UCB units using the
CliniMACSsystem. Prior tobankinginliquid nitrogen thecollected
UCB units used for this study (n=16) have been reduced for red
blood cells and volume using EloHAESH separation. The mean
volume of 111634 ml (range 72–175 ml) and mean WBC count of
1,5036455610
6 cells (range 772–2,380610
6) was reduced to 25 ml
with a WBC count of 1,0856357610
6 cells (range 600–1,721610
6)
containing 3.7861.95610
6 CD34
+ cells (range 1.73–8.72610
6)
(Table 1). Cryopreserved UCB units were thawed and prepared for
CD34
+ selection using CliniMACS buffer containing clinical-grade
DNAse.The recovery ofCD34
+ cells afterthawing was76%616%,
which resulted ina total yield of 2.7961.59610
6 CD34
+ cells (range
1.43–8.12610
6) for the selected UCB units (Table 1). Next, CD34
+
cells were enriched using the CliniMACS cell separator resulting in
a mean recovery of 71%611% (range 50–91%) (Table 2). The
purity of the enriched CD34
+ product was 67%614% (range 44–
92%). Total recovery after thawing and CD34 enrichment was
53%615% (range 33–82%) with a mean CD34
+ cell number of
1.96610
661.27610
6 (range 0.89–6.34610
6) (Table 2). These
results demonstrate that CD34
+ cells can be efficiently enriched
from volume-reduced and cryopreserved UCB units providing a
clinical-grade starting product for the NK cell generation and
expansion culture process.
Enriched CD34
+ UCB cells can be efficiently expanded
using static cell culture bags
Previously, research scale experiments in 6-well plates showed
that CD34
+ cells, enriched from frozen UCB units, can be
Table 1. Characteristics of the UCB units after EloHAES separation and cryopreservation.
Collected UCB Volume reduced UCB Thawed UCB
Volume NCs NCs CD34
+ cells NCs CD34
+ cells Recovery CD34
+ cells
ml x10
6 x10
6 x10
6 x10
6 x10
6 %
Donor 1 88 1294 790 3.90 368 2.96 76
Donor 2 151 1857 1312 5.88 469 3.73 63
Donor 3 141 1734 1378 4.96 653 3.23 65
Donor 4 87 1992 1588 8.72 819 8.12 93
Donor 5 119 1821 1106 3.68 583 2.28 62
Donor 6 153 1775 1519 3.17 829 2.15 68
Donor 7 152 1733 978 2.08 440 2.06 99
Donor 8 72 1210 760 2.70 403 2.07 77
Donor 9 78 772 600 3.96 248 1.84 46
Donor 10 97 927 616 1.73 386 1.69 98
Donor 11 81 1207 974 2.82 479 2.52 89
Donor 12 175 2380 1721 6.90 943 3.96 57
Donor 13 95 1430 1008 3.04 558 2.66 87
Donor 14 77 857 680 1.75 273 1.43 82
Donor 15 88 1223 969 2.40 563 2.14 89
Donor 16 130 1829 1364 2.78 821 1.82 66
mean 111 1503 1085 3.78 552 2.79 76
SD 34 455 357 1.95 210 1.59 16
median 96 1581 993 3.11 518 2.21 76
min 72 772 600 1.73 248 1.43 46
max 175 2380 1721 8.72 943 8.12 99
The table summarizes the processing of 16 UCB units used for CD34
+ enrichment after collection, volume reduction and thawing process. Nucleated cells (NCs) were
counted with the AcT10 counter (Beckman coulter). CD34
+ cells were enumerated by single platform flow cytometry analysis. Results are depicted as mean, standard
deviation, median, minimum (min) and maximum (max) volume, number of cells or percentages, respectively.
doi:10.1371/journal.pone.0020740.t001
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using our two step ex vivo culture process [18]. To translate this
protocol into a closed culture system, we have tested ex vivo
expansion of CD34
+ UCB cells for two weeks in static Vuelife
TM
AC culture bags using CD34
+ expansion medium I (day 0–9) and
medium II (day 9–14). The mean total cell expansion for all
experiments (n=7) was 39614 and 160669 fold after 1 and 2
weeks of culture, respectively (data not shown). These results were
similar to the rate of expansion of 192682 (n=7) obtained after 2
weeks in 6-well plates (data not shown), and indicate that selected
CD34
+ cells from cryopreserved UCB units can be efficiently
expanded during 2 weeks of culture in disposable bags.
Efficient expansion of highly pure NK cell products using
a bioreactor
Next, we investigated whether the bag-expanded CD34
+ UCB cells
could be differentiated and further expanded into CD56
+CD3
2 NK
cells. First, we continued the differentiation process in the same static
bags as used for CD34
+ cell expansion. Therefore, we added NK cell
differentiation medium containing SCF, IL-7, IL-15 and IL-2 to the
bag cultures from day 14 onward. The mean total cell expansion after
6 weeks of culture in the static bags was ,1,300 fold (range 759–1,770;
n=3), generating NK cell products of 0.9-1.9610
9 CD56
+CD3
2 NK
cells (Figure 1A and Table 3). However, ex vivo generation of
CD56
+CD3
2 NK cells in bag cultures yielded in a purity of
71%69% (Figure 1B and Table 3). The remaining non-NK cells in
the product represented CD14
+and/or CD15
+mature monocytic and
myelocytic cells, but no CD34
+ cells nor CD3
+ Tc e l l sa n dC D 1 9
+ B
cells could be detected (data not shown). Because differentiation of the
NK cell products was sub-optimal in the bag cultures, we next tested
whether differentiation of the bag-expanded CD34
+ cultures into the
NK cell lineage could be improved using an automated bioreactor.
Therefore, in a next set of experiments expanded CD34
+ UCB cells
were transferred at day 14 of culture into a bioreactor system with a
minimal volume of 250 ml for starting the NK cell differentiation
process. Although the mean total cell expansion at 6 weeks of culture in
the bioreactor cultures, which was ,2,100 fold (range 1,435–2,657;
n=4; Figure 3C and Table 3), was not significantly higher compared
to the bag-expanded NK cells, the differentiation and expansion rate of
NK cells was significantly better in the bioreactors (Figure 1D and E).
Importantly, ex vivo generation of CD56
+CD3
2 NK cells in bioreactors
yielded highly pure (92%62 % ;n=4 )N Kc e l lp r o d u c t sw i t hat o t a l
NK cell number of 1.6-3.7610
9 CD56
+CD3
2 NK cells (Table 3).
Because of the very high NK cell purity of the bioreactor expanded
products, only a small population (,5%) of mature CD14
+ and/or
CD15
+monocytic cells could bedetected,but no CD34
+cells, CD3
+T
cells or CD19
+ B cells were found (data not shown). Furthermore, we
compared the expression of various NK cell specific surface antigens
and NK cell function in degranulation assays on static bag and
bioreactor generated NK cell products (Figure S1). The bioreactor
cultures show a higher expression of activating receptors such as
CD314 (NKG2D) and NCRs (i.e. CD337, CD336, CD335) (Figure S1
A). This correlated with a higher degranulation of 27% of bioreactor-
expanded NK cells towards K562 compared to 14–18% for NK cells
from static bag cultures (Figure S1 B). These data demonstrate that the
Table 2. Characteristics of the CD34 CliniMACS separation on thawed UCB units.
CD34+ positive fraction
Recovery after CD34
enrichment only (%)
CD34
+ cell
content (%)
CD34
+
cells (x10
6)
Recovery of CD34
+ cells
after processing (%)
Donor 1 50 52 1.47 38
Donor 2 53 77 1.99 34
Donor 3 73 70 2.36 48
Donor 4 78 92 6.34 73
Donor 5 76 54 1.74 47
Donor 6 79 65 1.70 54
Donor 7 82 64 1.70 82
Donor 8 69 73 1.42 53
Donor 9 72 88 1.32 33
Donor 10 76 69 0.89 51
Donor 11 91 65 2.29 81
Donor 12 70 59 2.79 40
Donor 13 55 84 1.47 48
Donor 14 76 67 1.09 62
Donor 15 71 44 1.52 63
Donor 16 65 52 1.19 43
mean 71 67 1.96 53
SD 11 14 1.27 15
median 73 66 1.61 50
min 50 44 0.89 33
max 91 92 6.34 82
The table summarizes the results of the CD34
+ enrichment procedure of 16 UCB units. CD34
+ cells were enumerated by single platform flow cytometry analysis. Results
are depicted as mean, standard deviation, median, minimal (min) and maximal (max) number of cells or percentages.
doi:10.1371/journal.pone.0020740.t002
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followed by efficient NK production in bioreactor systems result in a
efficient production of pure NK cell products for adoptive immuno-
therapy trials.
The effect of washing on recovery, phenotype and
function of expanded NK cells
After showing that CD34
+ UCB cells could be efficiently
enriched from frozen cord blood and successfully cultured into a
pure NK cells product using a closed cell culture process, we
optimized downstream processing using a closed system washing
procedure. Therefore, final NK cell batches were washed two
times with 0.5 liter CliniMACS buffer containing 0.5% HSA in
transfer bags. After this washing procedure the total cell culture
volume of 1 liter was reduced and exchanged to 150 ml infusion
buffer. The final dilution factor of this washing procedure was
between 629–1,008 fold (n=3), with a recovery of 82%65%
CD56
+CD3
27AAD
2 NK cells (n=3). Cytotoxicity and CD107a-
based degranulation assays using K562 as target cells showed that
the cytolytic activity of the NK cell product before and after
washing was not affected (Figure 2A and B). Moreover, washing of
the expanded NK cells did not negatively influence the high
expression of the activating receptors NKG2D (CD314), NKR-P1
(CD161), 2B4 (CD244), NKp30 (CD337), NKp46 (CD335) and
Figure 1. Ex-vivo generation of CD56
+ NK cells from cryopreserved CD34
+ UCB cells. CD34-enriched UCB cells were expanded for two
weeks and subsequently differentiated into NK cells for four additional weeks. Cell cultures were weekly analyzed for cell numbers and phenotype
using flow cytometry. (A) Fold expansion of total cells for each donor after initial seeding of enriched CD34
+ UCB cells during 6 weeks of culture using
static Vuelife
TM cell culture bags. (B) CD56
+ cell frequency for each donor during the 6 week culture period for static bag cultures. (C) Fold expansion
of total cells for each donor after initial seeding of enriched CD34
+ UCB cell population during 6 weeks of culture using single use bioreactors. (D)
CD56
+ cell frequency for each donor during the 6 week culture period for bioreactor cultures. (E) Mean total CD56
+ NK cell expansion during 4 weeks
of differentiation using static bag (n=3) or bioreactor cultures (n=4). Data are depicted as mean 6 SD. The asterisk (*) represents a p-value of ,0.05.
doi:10.1371/journal.pone.0020740.g001
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+
UCB-derived NK cells (UCB-NK) for immunotherapy could be
efficiently washed using a closed process without loss of functional
and phenotypical characteristics of the bioreactor-expanded
NK cells.
UCB-NK cell therapy products fulfill specific release,
biosafety and stability tests
During the validation runs of our closed culture and washing
process, we monitored purity, cell numbers, viability, phenotype,
Figure 2. Functional activity of ex vivo bioreactor-expanded NK cells before and after the washing process. (A) Cytotoxicity of ex vivo-
generated NK cells against K562 cells was analyzed after 18 hours of co-culture with unwashed (black bars) and washed (white bars) NK cells from
three different donors at an E:T ratio of 1:1 or 10:1. (B) Degranulation of ex vivo-generated NK cells against K562 was analyzed by CD107a expression
after 18 hours of co-culture after of unwashed (black bars) and washed (white bars) NK cells from three different donors at an E:T ratio of 1:1.
doi:10.1371/journal.pone.0020740.g002
Table 3. Overview of the quantity and quality of final UCB-NK products generated from enriched CD34
+ cells using static bags and
single use bioreactors.
Donor CD34
+ cells (x10
6) fold expansion CD56
+ cells (%) CD56
+ cells (x10
9)
static bag 7 1.7 1,770 63 1.9
8 1.4 759 80 0.9
9 1.3 1,291 70 1.2
bioreactor 10 0.9 2,549 95 2.2
13 1.5 1,764 90 2.4
15 1.5 2,657 92 3.7
16 1.2 1,435 92 1.6
The table summarizes the generation of UCB-NK cell therapy products generated in static bags (Donor 7, 8 and 9) or bioreactors cultures (Donor 10, 13, 15 and 16).
doi:10.1371/journal.pone.0020740.t003
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validation runs in the bioreactor resulted in a final cell product
containing.90% viable CD56
+CD3
27AAD
2 NKcells,and CD3
+
T cells could not be detected (,0.01%). Importantly, cytogenetic
analysis showed that the NK cell products displayed a normal
karyotype. In addition, extensive testing was performed to ensure
that our process was free of bacterial, fungal, mycoplasma and
endotoxin contamination (Table 4). These tests were performed at
the end of the NK cell production and after the washing procedure,
and were negative or below specifications in all validation runs. The
presence of residual SCF, IL-7, IL-15 and IL-2, which were used in
the NK cell differentiation medium, was tested by specific ELISA.
After washing the NK cell products, the cytokine concentrations
were below the specified range of ,25 pg/ml SCF, IL-7 and IL-15
and ,1 U/ml IL-2.
Since we intend in our phase I clinical trial to infuse freshly
prepared NK cell products without cryopreservation, we deter-
mined the stability of the NK cells in order to establish a time
frame for the product release testing to be finished. Therefore, we
stored UCB-NK cell products in infusion buffer (i.e. 0.9% NaCl
plus 5% HSA) at 4uC or RT, and tested purity and viability at 24,
48 and 72 hours. We did not detect a decrease in purity of the NK
cell product over time and also detected no differences between
storage at 4uC or RT (Figure 4A). Only a small decline in viability
of CD56
+7AAD
2 NK cells was observed at day 2 or 3 after
storage at both 4uC and RT (Figure 4B). A more detailed view on
the stability tests regarding the expression of several inhibitory and
activating NK cell receptors showed a stable percentage of
CD159a (NKG2A) and CD314 (NKG2D) positive NK cells, but
the expression of the NCRs CD337, CD336, CD335 declines over
time irrespective of storage at 4uC or RT (Figure S2 A–D). Our
specification for NK cell infusion requires a minimum of 70%
viability, and therefore we have set our expiration time for UCB-
NK cells at 24 hours after final formulation.
Collectively, these results demonstrate the feasibility to generate
highly pure, safe and active UCB-NK cell therapy products using
a fully closed cell culture and downstream manufacturing process
for evaluating in a phase I dose escalation trial in poor-prognosis
patients with AML.
Discussion
To date only a few trials have investigated adoptive NK cell
infusions in patients with cancer primarily due to difficulties in
isolating high numbers of NK cells from regular leukapheresis
products [6–11]. Furthermore, ex vivo expansion protocols still deal
with technical disadvantages by using supportive feeder cell lines
that could lead to regulatory problems producing NK cell products
for large-scale and multi-center trials [12–16]. Here, we report the
successful translation of our recently developed, highly efficient cell
culture protocol for the ex vivo generation of functional NK cell
products from UCB-derived hematopoietic stem and precursor
cells into a clinical applicable GMP procedure. Previously, we
described a highly potent culture method for the ex vivo generation
of fully active NK cells efficiently targeting AML and melanoma
cells [18]. This cytokine-based, feeder cell-free culture process uses
only human or human recombinant proteins. To translate this NK
cell bioprocess into a GMP compliant procedure, we first
optimized clinical-grade enrichment of CD34
+ cells from cryo-
preserved UCB. Thereafter, we validated ex vivo generation of
UCB-NK cell therapy products using a closed production process
optimized for NK cell differentiation using bioreactors.
A number of studies reported previously about closed system
immunomagnetic beads selection of CD34
+ cells from cryopre-
served UCB [21–24]. Most of these studies used the Isolex300i or
the CliniMACS system, but currently only the CliniMACS system
Figure 3. Flow cytometry analysis of ex vivo bioreactor-expanded NK cells before and after washing. The CD56
+CD3
2 lymphocytes were
analyzed of unwashed (A) and washed (B) NK cell products. A representative example out of three different NK cell products is shown.
doi:10.1371/journal.pone.0020740.g003
Clinical-Grade HSC-Derived NK Cells
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20740is still available for clinical application. Due to technical
modifications such as different tubing sets for the CliniMACS
(i.e. tubing 150 in older studies and tubing 161-01 in our study) and
differences in the cord blood processing prior to cryopreservation
one may expect variations for the efficiency of the selection
procedure. For instance, the influence of different methods of
volume reduction and removal of red blood cells on the recovery
of CD34
+ UCB cells has been widely studied [25–28]. We used the
well-established EloHAESH separation method in our study [29].
Previous studies using the CliniMACS device showed a median
recovery of 31% UCB CD34
+ cells (n=10) [21,24]. We obtained
a higher overall median CD34
+ UCB cell recovery of 50%
(n=16), which is most likely due to the use of a highly efficient
thawing procedure providing a more optimal starting cell product
for CD34
+ cell selection compared to previous studies. Querol et
al. [22] used a similar thawing procedure with Pulmozyme on
HES-treated cord blood units, however they used the Isolex-300-
SA for CD34 selection. But they used a similar cord blood cohort,
consisting of 1.1160.5610
9 nucleated cells (NCs) and
3.6462.54610
6 CD34
+ cells, compared to ours with
1.0860.4610
9 NCs and 3.7861.95610
6 CD34
+ cells. Using an
up-to-date CliniMACS system, we isolated CD34
+ UCB cell
numbers of 1.9661.27610
6 cells with a purity of 67%614% and
a recovery of 53%615 from the used UCB cohort. These results
are very similar to those of Querol et al. [22], which is
1.9461.55610
6 CD34
+ cells with a purity of 69%616% and a
recovery of 52%612%. These findings illustrate that our current
thawing and CD34
+ selection procedures provides excellent
preparation of a CD34
+ UCB cell product for direct use or graft
manipulation.
After optimizing CD34 enrichment from cryopreserved UCB,
we investigated whether CliniMACS-enriched CD34
+ UCB cells
could be efficiently expanded and further differentiated into the
NK cell lineage using a closed cell culture system. Recently, Sutlu
et al. reported that large amounts of highly active NK cells can be
produced from peripheral blood mononuclear cells (PBMCs) in a
closed, automated, bioreactor under feeder-free conditions [17].
Interestingly, bioreactor cultures yielded a final product containing
a clinically relevant NK cell dose (mean 9.8610
8 NK cells).
Moreover, they observed that NK cells expanded in a bioreactor,
compared to flasks and bags, displayed higher cytotoxic activity
possibly attributed to a higher expression level of NKp44. In
agreement with the studies of Sutlu et al., we also obtained a much
better purity, functionality and significant better NK cell
expansion using the Wave
TM or Biostat
TM bioreactor systems
during the NK cell differentiation process. For efficient NK cell
generation it seems, that an optimal gas exchange for the cell
suspension could be provided by rocking or waving of the cell
suspension. Finally, we performed safety and release tests on the
NK cell end products (summarized in Table 4). The genetic
stability was analyzed by karyotype analysis and all NK cell
products had a normal karyotype. Furthermore, all generated
products were negative for bacterial, fungal or mycoplasm
contamination. After washing of the product, the volume was
reduced to 150 ml prior infusion. Cytokine levels were efficiently
reduced to below 25 pg/ml. Immunophenotyping analysis dem-
onstrated high purity, viability and activated phenotype of the NK
cell product with the complete absence of CD3
+ T cells. We
additionally demonstrate, that the cell culture process is safe and
that the product could be further processed, stored and safely
released for patients.
In conclusion, we successfully adapted our method into a closed-
system bioprocess for production of allogeneic NK cell batches
under GMP conditions, in order to utilize ex vivo-expanded NK
cells for adoptive immunotherapy in poor-prognosis AML
patients. Large-scale experiments using gas-permeable culture
Table 4. Product release testing criteria and results of the final NK cell products.
Test Method Specification Donor 10 Donor 13 Donor 15 Donor 16
NK cell number FCM CD56
+CD3
2 NK cells 2.2610
9 2.4610
9 3.7610
9 1.6610
9
Purity FCM .70% CD56
+CD3
2 NK cells 95% 90% 92% 92%
Viability FCM .70% 7-AAD negative n.a. 98% 97% 93%
Phenotype FCM .30% positivity for CD56,
CD94, NKG2A, NCR and NKG2D.
yes yes yes yes
Karyotyping Cell culture Normal karyotype yes yes yes yes
Recovery FCM % CD56
+CD3
2 NK 7-AAD
negative cells.
n.a. 83% 86% 76%
Content CD3
+ T-cells FCM ,1610
4 CD3
+ T cells/kg body
weight of the patient
n.d. n.d. n.d. n.d.
Content CD19
+ B-cells FCM ,1610
4 CD19
+ B cells/kg body
weight of the patient
n.a. n.a. n.a. n.a.
Sterility Culture Negative for bacterial and
fungal contamination
negative negative negative negative
Mycoplasm Luminescence assay Negative for mycoplasm
contamination
negative negative negative negative
Endotoxin LAL assay ,0.25 EU/ml 0.08 0.02 0.01 0.01
Absence of cytokines ELISA ,25 pg/ml IL-2, IL-7, IL-15
and SCF.
yes yes yes yes
The table shows an overview of product release tests and product specifications for the ex-vivo generated NK cells using a closed cell culture process. The table
summarized the facts needed to provide a certificate of analysis to release an UCB-NK cell therapy product for a patient. n.a. = not analyzed in validation runs but these
parameters will be scored for the clinical production and the certificate of analysis. n.d.: not detected; the test do not show any positive events. yes = the results of the
test fulfill the specification relevant for the certificate of analysis.
doi:10.1371/journal.pone.0020740.t004
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bioreactor systems resulted in the generation of products
containing more than 3.5610
9 NK cells with a purity of up to
95%. Furthermore, the UCB-NK-cell products could be finally
processed for infusion using a closed system and be stored until all
product control tests will be available in order to release the UCB-
NK-cell therapy product. The safety and toxicity of infusing these
allogeneic ex vivo-expanded UCB-NK cell therapy products will be
investigated in phase I dose escalation trial in elderly AML patients
not eligible for allogeneic stem cell transplantation.
Materials and Methods
Cell lines
Cell line K562 (LGC Standards, Wesel, Germany) was cultured
in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen,
Carlsbad CA, USA) containing 50 U/ml penicillin, 50 mg/ml
streptomycin and 10% fetal calf serum (FCS; Integro, Zaandam,
the Netherlands).
Isolation of CD34
+ stem and progenitor cells
UCB units have been obtained at birth after normal full-term
delivery after written informed consent with regard of scientific
use from the cord blood bank of the Radboud University
Nijmegen Medical Center (RUNMC, Nijmegen, The Nether-
lands). The use of these UCB units for our study was approved by
the RUNMC Institutional Review board. UCB samples were
stored at room temperature and processed within 24 h after
collection. Before storage, the red blood cell content has been
reduced using standard EloHAESH separation and the mononu-
clear cells have been washed, cryopreserved and stored in liquid
nitrogen [29]. Stored UCB units were thawed at 37uC and
resuspended in thawing buffer consisting of CliniMACS PBS/
EDTA buffer (Miltenyi Biotech, Bergisch Gladbach, Germany),
5% HSA (Sanquin blood bank, Amsterdam, The Netherlands),
3.5 mM MgCl2 (Pharmacy Department, RUNMC, Nijmegen,
The Netherlands) and 100 U/ml Pulmozyme (Roche, Almere,
The Netherlands). Thawed UCB cells were incubated for 30
minutes at room temperature (RT) and subsequently centrifu-
gated. After two washing steps, thawed UCB cells were
resuspended in 8 ml washing buffer consisting of CliniMACS
PBS/EDTA buffer, 0.5% HSA, 3.5 mM MgCl2 and 100 U/ml
Pulmozyme and labeled for 30 minutes at RT with 0.75 ml
CliniMACS CD34 reagent (Miltenyi Biotech) and 1 ml Nanogam
(Sanquin blood bank, Amsterdam, The Netherlands). After
incubation, the CD34-labeled UCB sample was washed and
Figure 4. Stability tests of ex-vivo generated and processed NK cell products. (A) The NK cell content of the processed final product was
followed over time, while the products were either stored at 4uC or room temperature (RT) for a maximum of 3 days. The percentage of the CD45
+/
CD56
+ cells is displayed from 3 different stability tests. (B) Viability of the final NK cell product was followed over time, while the products were either
stored at 4uC or room temperature (RT). The percentage of the CD45
+/CD56
+/7-AAD
2 cells is displayed from 3 different stability tests.
doi:10.1371/journal.pone.0020740.g004
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iMACS cell separator was equipped with a closed disposable
CliniMACS tubing set type 161-01 (Miltenyi Biotech). The CD34
+
cell selection was performed using an automated program and
after the enrichment procedure, the CD34
+ cell fraction was
collected, and the cell number and purity were analyzed by flow
cytometry. Finally, the obtained CD34
+ UCB cells were used
directly for the NK cell generation bioprocess.
Ex vivo expansion and differentiation of CD34-positive
progenitor cells
CD34
+ UCB cells were transferred into Vuelife
TM bags 290AC
or 750AC (Cellgenix, Freiburg, Germany), and expanded and
differentiated according to culture method III as described
previously with some minor modifications [18]. In brief, for day
0–9 Expansion Medium I was used consisting of Glycostem Basal
Growth Medium (GBGMH) for cord blood (CB) (Clear Cell
Technologies, Beernem, Belgium) supplemented with 10% human
serum (HS; Sanquin Bloodbank, Nijmegen, The Netherlands), a
high-dose cytokine cocktail containing SCF, Flt3L, TPO and IL-7
(all CellGenix, Freiburg, Germany) and a low-dose cytokine
cocktail consisting of GM-CSF (Neupogen) (Amgen, Breda, The
Netherlands), G-CSF and IL-6 (both CellGenix, Freiburg,
Germany). Between day 10 and 14, Expansion II medium was
used in which TPO was replaced by IL-15 (CellGenix, Freiburg,
Germany). During the first 14 days of culture, low molecular
weight heparin (LMWH) (ClivarinH; Abbott, Wiesbaden, Ger-
many) was added to the expansion medium. Cell cultures were
refreshed with new medium every 2–3 days, and adjusted to a cell
density of .0.5610
6/ml. Cultures were maintained in a 37uC,
95% humidity, 5% CO2 incubator. Expanded cultures in
Vuelife
TM bags were either maintained in Vuelife
TM bags or
transferred to a bioreactor at around day 14. We have used both
the single use WAVE Bioreactor
TM System 2/10 (GE Health,
Uppsala, Sweden) and BIOSTATH CultiBag RM system (Sarto-
rius Stedim Biotech, Go ¨ttingen, Germany). From day 14 onward,
expanded CD34
+ UCB cells were differentiated and further
expanded using NK cell differentiation medium. This medium
consisted of Glycostem Basal Growth Medium (GBGMH) for cord
blood (CB) as used for the CD34 expansion step supplemented
with 10% HS, the low-dose cytokine cocktail (as previously
mentioned) and a new high-dose cytokine cocktail consisting of IL-
7, SCF, IL-15 and IL-2 (ProleukinH; Chiron, Mu ¨nchen,
Germany). The cell density was checked two times a week and
adjusted to ,1.0610
6 cells/ml by the addition of GBGMH NK
cell differentiation medium. The conditions of the bioreactor were
as follows: temperature 37uC, CO2 5%, airflow 0.1–0.2 l/min,
rocking rate 10/min, rocking angle of 6u.
Flow cytometry
Cell numbers and expression of cell-surface markers were
determined by flow cytometry. For immunophenotypical staining,
cells were incubated with the appropriate concentration of antibodies
for 30 min at 4uC. After washing, cells were resuspended in CoulterH
IsotonH II Diluent (Beckman Coulter) and analyzed using the Coulter
FC500 flow cytometer (Beckman Coulter). For determining the
content of CD34
+ cells in the UCB and the purity of the CD34
selected cells the following monoclonal antibodies were used: CD45-
FITC (J33) and CD34-PE (581) (both from Beckman Coulter,
Woerden, The Netherlands). The population of living CD34
+ cells
was determined by exclusion of 7AAD (Sigma, Bornem, Belgium)
positive cells. Analysis was performed according to the most actual
ISHAGE protocol. The purity of the end product after washing was
determined using the following monoclonal antibodies were used:
CD3-FITC (UCHT1) (Beckman Coul t e r ,W o e r d e n ,T h eN e t h e r -
lands); CD56-PE (NCAM16-2) (BD Biosciences Pharmingen, Breda,
The Netherlands), anti-CD45-ECD (J33) (Beckman Coulter, Woer-
den, The Netherlands). The population of living CD56
+ cells was
determined by exclusion of 7AAD (Sigma) positive cells. Ten color
analysis was used to determine the phenotype of the cultured NK
cells. The following monoclonal antibodies were used in the
appropriate concentration: CD16-FITC (NKP15), CD336(NKp44)-
PE (Z231), CD3-ECD (UCHT1), CD337(NKp30)-PC5.5 (Z25),
CD335(NKp46)-PE-Cy7 (BAB281), CD314(NKG2D)-APC (ON72),
CD244(2B4)-APC-alexa700 (C1.7.1), CD56-APC-Alexa750 (N901),
CD161-PB (191B8), CD45-PO (J33) (all provided by Beckman
Coulter, Marseille, France). The acquisition was performed on the
Navios
TM flowcytometer and the data were further analyzed using the
Kaluza
TM software (all from Beckman Co u l t e r ,M i a m i ,F l o r i d a ,
USA).
Flow cytometry-based cytotoxicity and degranulation
studies
Flow cytometry-based cytotoxicity assays were performed as
described previously [18,30]. Briefly, after incubation for 4 h or
overnight at 37uC, 50 ml supernatant was collected and stored at
220uC for later use to measure cytokine production. Cells in the
remaining volume were harvested and the number of viable target
cells was quantified by flow cytometry. Target cell survival was
calculated as follows: % survival = {[absolute no. viable CFSE
+
target cells co-cultured with NK cells]/[absolute no. viable CFSE
+
target cells cultured in medium]}*100%. The percentage specific
lysis was calculated as follows: % lysis = {100-[% survival]}.
Degranulation of NK cells during co-culture was measured by cell
surface expression of CD107a [31]. After 18 hrs of incubation at
37uC, the percentage of CD107a
+ cells was determined by flow
cytometry.
Preparation of the final NK cell product
At the end of culture, NK cells were harvested, and the number
and viability of CD56
+ cells was determined by flow cytometry
and ACT counter (Beckman Coulter). The UCB-NK-cell product
was transferred into 600 ml transfer bags (Baxter, Deerfield, USA),
centrifugated 200 g for 15 min without break and the supernatant
was collected for testing of bacterial, fungal and mycoplasm
contamination. NK cells were resuspended and washed twice with
500 ml CliniMACS PBS/EDTA buffer supplemented with 0.5%
HSA (Sanquin Blood Bank, Amsterdam, The Netherlands). After
washing, NK cells were resuspended in infusion buffer consisting
of NaCl 0.9% + 5% HSA. Finally, viable number of CD56
+CD3
2
NK cells in the end-product was determined by flow cytometry
and the concentration of residual SCF, IL-7, IL-15 and IL-2 was
measured by ELISA (R&D Systems, Abingdon, Oxon, UK).
Karyotyping of the NK cell product
Cytogenetic analysis was performed on the final NK cell
products according to standard methods. In total 20 metaphases
were G-banded using trypsin and Giemsa (GTG) and were
examined per case. Karyotypes were described according to ISCN
2009 [32].
Sterility testing of the NK cell product
Before and after washing in bags, samples were taken and
processed to check for bacterial and fungal contaminations. These
samples were transferred to Bactec Ped plus flasks (BD). Bacterial
growth till day 6 should be reported as positive. The testing was
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The Netherlands.
Mycoplasma testing
Mycoplasma detection was performed on final products using
the MycoAlertH Mycoplasma detection kit (Lonza, Rockland,
USA) following the manufacturer’s instructions. The signals were
measured with the Fluostar Optima (BMG Labtech, IJsselstein,
The Netherlands).
Endotoxin test
Endotoxin level in the final products was determined using the
chromogenic Limulus Amebocyte Lysate (LAL) assay (Charles
River Endosafe, Charleston, SC, USA) following the manufactur-
er’s guidelines by the Pharmacy Department, RUNMC, Nijme-
gen, The Netherlands. A level of ,0.25 EU/ml was set as negative
endotoxin limit.
Cytokine detection
Cytokine levels in the final products were determined using
ELISA. Briefly, Maxisorp 96-well plates (NUNC) were coated
overnight with 1 mg/ml of monoclonal coating antibody for IL-2,
IL-7, IL-15 and SCF (all from R&D systems, Abingdon, Oxon,
UK). For sample detection, biotinylated antibodies were added for
IL-2 (0.2 mg/ml polyclonal Ab), IL-7 (0.2 mg/ml polyclonal Ab),
IL-15 (0.25 mg/ml monoclonal Ab) and SCF (0.05 mg/ml
polyclonal Ab), respectively. The extinction was measured by the
TiterTek Multiscan MCC/340 plate reader (Titertek, Huntsville,
AL). Concentrations of triplicate measurements were determined
using a standard curve ranging between 1 to 2000 pg/ml of the
specific cytokine.
Statistics
Results from different experiments are described as mean 6
standard deviation of the mean (SD), range and median. Statistical
analysis was performed using students t-test. A p-value of ,0.05
was considered statistically significant.
Supporting Information
Figure S1 Flow cytometry analysis for phenotype and
function of ex vivo expanded NK cells using static bags
or bioreactor cultures. (A) The CD45
+CD56
+CD3
2 lympho-
cytes were analyzed for several NK cell specific surface antigens
for bioreactor cultures (black bars) and static bags (grey bars). (B)
NK cell functionality was tested in a CD107a degranulation assay
and the percentage of degranulating cells (CD107
+) was analyzed.
Bioreactors cultures from donor 10 and 13 were compared with
static bag cultures from donor 7 and 9 in an overnight co-culture
with an E:T ratio of 1:1.
(TIF)
Figure S2 Stability tests of ex-vivo generated and pro-
cessed NK cell products. (A–D) The CD45
+CD56
+CD3
27AAD
2
lymphocytes from two different donors (A&B and C&D) were analyzed
for several NK cell specific surface antigens and followed over time. (A
and C) The products were either stored at 4uC or (B and D) at room
temperature (RT) for a maximum of 3 days.
(TIF)
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